Every material Form 8-K Outlook Therapeutics, Inc. has filed with the SEC since August 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, but the company has until March 24, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq notice dated September 25, 2026 cites a closing bid below $1.00 for 30 consecutive business days under Listing Rule 5550(a)(2)
Compliance Date is March 24, 2027, 180 calendar days under Rule 5810(c)(3)(A)
Company may be eligible for a second 180-day period and may need a reverse stock split; if not compliant, Nasdaq would issue a delisting notice that the company could appeal
Outlook Therapeutics disclosed that on September 16, 2026, it set the wholesale acquisition cost for LYTENAVA in the United States at $485 per vial. The filing is a routine pricing disclosure and does not include sales, revenue, or guidance figures.
Wholesale acquisition cost for LYTENAVA in the U.S. set at $485 per vial
Price established on September 16, 2026
Disclosed in an Item 8.01 (Other Events) filing dated September 18, 2026
Outlook Therapeutics said its CFO Lawrence A. Kenyon will leave the role effective September 1, 2026, and the Board appointed Kevin Lundquist as CFO, Treasurer and principal financial and accounting officer from the same date. Kenyon will stay on in a non-executive role through September 30, 2026, and will step down from the Board, which will shrink to eight directors. The company says the departure was not due to any disagreement over accounting, financial reporting or operations.
Kevin Lundquist, 58, was CFO of CapsoVision Inc. from October 2024 to February 2026 and previously was CFO of Abzena Biologics from 2022 to 2023.
Lundquist's base salary is $450,000, with a target bonus of 50% of salary and an option to buy 500,000 shares.
Kenyon's separation agreement provides a lump sum of 12 months' base salary, $20,000 and his full 2026 target bonus, plus full option vesting and up to 12 months of COBRA benefits.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Outlook Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →